Literature DB >> 32786803

The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents.

Stanley T Crooke1, Punit P Seth1, Timothy A Vickers1, Xue-Hai Liang1.   

Abstract

Recent progress in understanding phosphorothioate antisense oligonucleotide (PS-ASO) interactions with proteins has revealed that proteins play deterministic roles in the absorption, distribution, cellular uptake, subcellular distribution, molecular mechanisms of action, and toxicity of PS-ASOs. Similarly, such interactions can alter the fates of many intracellular proteins. These and other advances have opened new avenues for the medicinal chemistry of PS-ASOs and research on all elements of the molecular pharmacology of these molecules. These advances have recently been reviewed. In this Perspective article, we summarize some of those learnings, the general principles that have emerged, and a few of the exciting new questions that can now be addressed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32786803     DOI: 10.1021/jacs.0c04928

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  16 in total

Review 1.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

Review 2.  Antisense technology: A review.

Authors:  Stanley T Crooke; Xue-Hai Liang; Brenda F Baker; Rosanne M Crooke
Journal:  J Biol Chem       Date:  2021-02-16       Impact factor: 5.157

3.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

4.  Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.

Authors:  Ya-Wen Yang; Bibek Poudel; Julia Frederick; Poonam Dhillon; Rojesh Shrestha; Ziyuan Ma; Junnan Wu; Koji Okamoto; Jeffrey B Kopp; Sheri L Booten; Danielle Gattis; Andrew T Watt; Matthew Palmer; Mariam Aghajan; Katalin Susztak
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

5.  Pnictogen-Centered Cascade Exchangers for Thiol-Mediated Uptake: As(III)-, Sb(III)-, and Bi(III)-Expanded Cyclic Disulfides as Inhibitors of Cytosolic Delivery and Viral Entry.

Authors:  Bumhee Lim; Takehiro Kato; Celine Besnard; Amalia I Poblador Bahamonde; Naomi Sakai; Stefan Matile
Journal:  JACS Au       Date:  2022-03-24

6.  Cyclic Thiosulfonates for Thiol-Mediated Uptake: Cascade Exchangers, Transporters, Inhibitors.

Authors:  Takehiro Kato; Bumhee Lim; Yangyang Cheng; Anh-Tuan Pham; John Maynard; Dimitri Moreau; Amalia I Poblador-Bahamonde; Naomi Sakai; Stefan Matile
Journal:  JACS Au       Date:  2022-03-22

Review 7.  RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.

Authors:  Nada Bejar; Trinh T Tat; Daniel L Kiss
Journal:  Curr Atheroscler Rep       Date:  2022-04-02       Impact factor: 5.967

Review 8.  Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma-Progress and Challenges.

Authors:  Victor E Nava; Pin-Yu Perera; Nirbhay Kumar; Maneesh Jain
Journal:  Vaccines (Basel)       Date:  2022-02-11

Review 9.  From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies.

Authors:  Hironori Adachi; Martin Hengesbach; Yi-Tao Yu; Pedro Morais
Journal:  Biomedicines       Date:  2021-05-14

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.